Abstract:Introduction: Pheochromocytoma/Paraganglioma (PPGL) present with an extremely variable clinical picture which ranges from dramatic, to mild, to silent, depending on tumor attitude to release catecholamines. Hypertension is the hallmark of these tumors but is not always present. Distinct differences of clinical manifestations exist in hypertensive pheochromocytomas (HPs) and normotensive pheochromocytomas (NPs), however the comparative analysis is lacking. Methods: The objective was to assess the clinical symptoms, hemodynamics, metabolism, radiological and histological features of patients with HPs and NPs. This study included 104 pheochromocytoma patients who were categorized into HPs (n = 69) and NPs (n = 35) groups. All clinical records were reviewed. Tumor samples were examined to determine the Adrenal Gland Scale Score and were available for measurement of gene transcriptions. Biochemical examinations of 95 subjects with primary hypertension (PH) were recorded for comparative study. Results: Patients with NPs showed lower proportion of clinical triad, inapparent metabolic disorders and lower urinary catecholamine levels than HPs, but higher than PH. Tumor weight positively correlated with 24 h urinary norepinephrine level in patients with HPs (P = 0.028), and tumor diameter negatively correlated with phenylethanolamine-N-methyltransferase (PNMT) immunohistochemistry (P = 0.011) in NPs but not in HPs. The Adrenal Gland Scale Score of NPs group was similar to that of HPs group. The positive percentage of epinephrine type (E-type) of catecholamine in HPs group was higher than that in the NPs. The transcript gene levels of PNMT, secretogranin II (SGII) and neuropeptide Y (NPY) from tissue samples were significantly lower in NPs than in HPs (P-PNMT = 0.038, P-SGII = 0.040, P-NPY = 0.032), while vesicular monoamine transporter 1 (VMAT1) had no difference between HPs and NPs (P-VMAT1 = 0.053). Conclusion: HPs and NPs have distinct differences in clinical, biochemical and pathological phenotypes, which are closely related with productions involved in tumor occurrence and development.

Expression significance of apoptosis-related bak gene protein in adrenal pheochromocytoma

Apoptosis and Apoptosis Related Gene Products in Pituitary Adenoma of Human

Apoptosis in Supratentorial Astrocytomas and Expression of Apoptosis Related Gene P53 and Bcl-2

The Expression and Significance of Tumor Marker in Malignant Pheochromocytoma

Expression of pGSK-3α/β (Tyr279/216) and XIAP proteins in cholangiocarcinoma and their clinical significance

Expression of Bcl-2、Bax and Bak in Laryngeal Squamous Cell Carcinomas

Expression and Effect of Adrenomedullin in Pheochromocytoma

[Detection and Clinical Significance of Apoptosis Related Protein in Local Advanced Rectal Cancer Patients with Preoperative Neoadjuvant Therapy].

Influence of Apoptin on Up-Regulation of the Expression of Bad and Bax

Expression of Bcl-2, Bcl-XL, Bax and Bak in acute leukemia cells and its clinical significance

AQP2 As a Diagnostic Immunohistochemical Marker for Pheochromocytoma And/or Paraganglioma

Prognostic Significance of Apoptosis Related Gene Family Bcl-2 in Human Breast Cancer

The expression of VDACs and Bcl2 family genes in pituitary adenomas: clinical correlations and postsurgical outcomes

Expression of Dab2 in different adrenocortical adenomas

Significance of Increased Apoptosis and Bax Expression in Human Small Intestinal Adenocarcinoma

In Situ Labeling Apotosis in Breast Cancer As Related to Prognosis

Adrenal pheochromocytoma impacts three main pathways: cysteine-methionine, pyrimidine, and tyrosine metabolism

Clinical and Pathological Characteristics of Hypertensive and Normotensive Adrenal Pheochromocytomas.

Vitiligo in association with human immunodeficiency virus infection

Expression and relationship between HIF-1α and BCL-2 in pulmonary adenocarcionma

Expression and Significance of Clusterin , Bcl- 2 and FasL in Prostate Cancer